Global Epilepsy Market Outlook, Prospect and Future 2023
Summary - A new market study, titled “Global Epilepsy Market
Research Report Forecast to 2023”has been featured on WiseGuyReports.
Epilepsy is a disorder of the brain characterized by
repeated seizures. A seizure is usually defined as a sudden alteration of
behavior due to a temporary change in the electrical functioning of the brain.
Normally, the brain continuously develops tiny electrical impulse in an orderly
pattern. The rising prevalence of epilepsy diseases and increasing healthcare
expenditure drive the growth of the market. However, high per patient treatment
cost and regulatory restriction on profitability may hamper the growth of the
market.
The global epilepsy market is expected to register a CAGR of
8.20% during the forecast period of 2018 to 2023. In 2017, the market was led
by the Americas with a 38.1% share. The market growth in this region is mainly
due to the increasing prevalence of epilepsy disorders among the geriatric
population. According to the statistics published by the Epilepsy Foundation of
America Organization, 1.3 to 2.8 million people were diagnosed with epilepsy
disease in the US in 2018.
The global epilepsy market has been segmented based on
condition, diagnosis and treatment, end user, and region.
The condition segment is further segmented into
drug-resistant epilepsy and others.
The global epilepsy market, by diagnosis and treatment, is
segmented into diagnosis and treatment.
The global epilepsy market, by end user, is segmented into
hospitals, clinics (family practitioners/ internal medicine), ambulatory
surgical centers (outpatient centers), diagnostic centers, and others.
Key Players
LivaNova PLC, GlaxoSmithKline PLC, Eisai Co. Ltd, Pfizer
Inc., Medtronic PLC, UCB SA, NeuroPace Inc, GW Pharmaceuticals PLC, Novartis
AG, Johnson & Johnson Services Inc., Abbott Laboratories, and others.
Study Objectives
• To provide a detailed analysis of the market structure
along with the forecast of various segments and sub-segments of the epilepsy
market
• To provide insights into factors affecting the market
growth
• To analyze the global epilepsy market based on various
tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market
segments and sub-segments with respect to regions and their respective key
countries
• To provide country-level analysis of the market with
respect to the current market size and future perspective
• To provide country-level analysis of the market for
segments by condition, diagnosis and treatment, end user, and region
• To provide strategic profiling of key players in the
market, comprehensively analyzing their core competencies and drawing a
competitive landscape for the market
• To track and analyze competitive developments such as
joint ventures, strategic alliances, mergers and acquisitions, new product
developments, and research and developments in the epilepsy market
Target Audience
• Biotechnology Companies
• Pharmaceutical Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global epilepsy market is expected to reach USD
9,509.20 million by 2023 from USD 5,931.74 million in 2017 and is expected to
register a CAGR of 8.20% during the forecast period from 2018 to 2023
• On the basis of condition, the drug-resistant epilepsy
segment accounted for the largest market share and is projected to register a
CAGR of 9.07% from 2018 to 2023
• Based on diagnosis and treatment, the treatment segment
accounted for the largest market share and is anticipated to register a CAGR of
7.91% by the year 2023
• Based on end user, the hospitals segment held the largest
market share of 29.3% in 2017 and is projected to register a CAGR of 8.29%
during the forecast period
• The Americas is expected to hold the largest share of the
global epilepsy market at a CAGR of 7.77% by 2023
• Asia-Pacific is the fastest growing market, which is
expected to register a CAGR of 8.86% by 2023
Regional Analysis
• Americas
o North America
US
Canada
o Latin America
Brazil
Rest of Latin America
• Europe
o Western Europe
Germany
France
UK
Italy
Spain
Rest of Western Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
Saudi Arabia
Rest of the Middle East
o Africa
FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4272159-global-epilepsy-market-research-report-forecast-to-2023
About Us:
Wise Guy Reports is part of the Wise Guy Research
Consultants Pvt. Ltd. and offers premium progressive statistical surveying,
market research reports, analysis & forecast data for industries and governments
around the globe.
Contact Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph:
+44 203 500 2763 (UK)
Comments
Post a Comment